EISAI CO
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease
Phase 2
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: E5555 100 mgDrug: E5555 50 mgDrug: E5555 200 mgDrug: Placebo
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT00540670
A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase 2
Completed
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Drug: E0302 (mecobalamin)
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT00445172
A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase 2
Completed
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Drug: E0302 (mecobalamin)Drug: Placebo
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 373
- Registration Number
- NCT00444613
Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures
- First Posted Date
- 2006-12-27
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT00416195
- Locations
- 🇱🇻
P. Stradina Clinical University Hospital, Riga, Latvia
🇱🇻Hospital Gailezers, Riga, Latvia
Phase I Clinical Study of E7389
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2012-03-08
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT00326950
Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women
Phase 3
Completed
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Drug: menatetranone
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT00165698
- Locations
- 🇨🇳
Beijing Hospital, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
A Study of E7070 in Patients With Gastric Cancer
Phase 1
Terminated
- Conditions
- Gastric Cancer
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2014-01-23
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT00165594
Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis
Phase 2
Completed
- Conditions
- Cervical DystoniaSpasmodic Torticollis
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 133
- Registration Number
- NCT00165776
The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia.
Phase 4
Completed
- Conditions
- Dementia With Vitamin B12 Deficiency
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- Eisai Co., Ltd.
- Registration Number
- NCT00165711
- Locations
- 🇨🇳
Chinese University of Hong Kong, Hong Kong, Hong Kong, China
A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
Phase 3
Completed
- Conditions
- Non-erosive Gastroesophageal Reflux Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-07-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 288
- Registration Number
- NCT00165646